NGS for Myeloid Neoplasm Evaluation

In this month's "Hot Topic," David Viswanatha, M.D., discusses updates to Mayo Clinic's next-generation sequencing (NGS) for myeloid neoplasm evaluation, involving new test targets, the rationale for new genetic regions, alignments with the World Health Organization (WHO) guidelines and germline predisposition targets.

0:00 Introduction
0:35 Outline
1:25 Current NGS
3:38 New Version NGSHM Panel
7:00 Alignment with ICC and WHO 2022 Update
9:00 Germline Predisposition
10:14 Why NGS?
13:00 Caveats and Challenges
15:40 Conclusions